New drug immunoglobulin could give three-year reprieve from Alzheimer's

Substance made from antibodies in human blood could be on the shelves in 10 years

Scientists have hailed a new drug for Alzheimer's disease after a trial successfully halted the mental decline associated with the condition for a period of three years.

Researchers found that patients who had injections every two weeks of the drug immunoglobulin, made from antibodies in human blood, showed no decline in cognition, memory, daily functioning or mood.

Immunoglobulin is normally given to patients who suffer from an immune deficiency, but it has also been found to protect the brains of those with early stage Alzheimer's. Each dose is extracted from the plasma of 1,000 blood donors.

Professor Clive Ballard, director of research at the Alzheimer's Society, said: "This is probably the most exciting drug we know about that is currently in the late stages of research.

"We now know it is safe but the real test will be whether these initial promising results can subsequently be replicated in larger groups."

Just 24 patients were tested with the drug in the study, who were given varying doses of the drug over different periods. A larger study is now underway. Professor Ballard added: "If the phase 3 trials are successful, and it can be made cost effective, this drug could be on the shelves within 10 years."

He added: "One in three people over 65 will develop dementia. While finding a cure is the Holy Grail of dementia research, it is also vitally important that we continue to fund studies like this if we are to develop more treatments to help people to live well with the condition."

However, the difficulty of producing immunoglobulin means it is not cheap, costing thousands of pounds per patient. The findings were presented at the Alzheimer's Association International Conference in Vancouver, Canada, yesterday.

There are currently three licensed drugs for the prevention of Alzheimers in the early and moderate stages but they are of limited effectiveness, slowing the progression of the disease in some patients but not in others.

Researchers studying immunoglobulin had previously reported its beneficial effects up to 18 months but have now extended the treatment for a further 18 months and found no decline in cognition and memory.

Scientists have been experimenting with immunotherapy – treatments to stimulate the immune system in Alzheimers patients – for several years but this is the first that has been shown to be both effective and safe.

The drug is thought to work by targeting the beta-amyloid protein, sweeping up and removing small fragments that form the amyloid plaques in the brain that lie behind the degenerative disease.

Normal Relkin, of Weill Cornell Medical College, New York, said: "This is the first study to report long-term stabilisation of Alzheimer's symptoms with intravenous immunoglobulin. While the small number of participants may limit the reliability of our findings , we are very enthusiastic about the results."

Early findings from the trial showed rates of brain shrinkage typical of Alzheimer's were halved in patients treated with the drug, as measured on MRI scans.

Independent Comment
blog comments powered by Disqus
News in pictures
World news in pictures
Life & Style blogs

Christian GPs and the morning after pill: Much needed clarification

Doctors are allowed to have personal beliefs, just as long as these beliefs do not interfere with th...

Justin Webb on the medical advances in tackling heart disease

BBC journalist Justin Webb talks about his experiences of the advances in preventing heart attacks a...

Record home price rises (and not just in London)

Plus the Property Power 100, and the best day to sell your home

       

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    SAP SD Consultant

    £475 - £476 per day + negotiable: Progressive Recruitment: SAP SD Contract Con...

    Maths Teacher- Reading

    Negotiable: Randstad Education Reading: Our client in Sonning Common, is looki...

    Science Teacher- Reading

    Negotiable: Randstad Education Reading: Our client in Sonning Common, is looki...

    Special Needs Teacher in Lewisham South London

    £27000 - £55000 per annum: Randstad Education London: Supply special education...

    Day In a Page

    'There is a battle going on inside us that is never discussed'

    Masculinity in crisis?

    'There is a battle going on inside us that is never discussed'
    Have US shock jocks gone too far?

    Have US shock jocks gone too far?

    An incendiary remark from Rush Limbaugh may be the beginning of the end for outspoken right-wing US broadcasters
    The ‘Beverly Hills’ of Surrey pays more income tax than big cities of the North

    The ‘Beverly Hills’ of Surrey

    Elmbridge pays more income tax than big cities of the North
    Heavenly Bodies

    Heavenly Bodies

    Michael Landy's artistic marriage made in heaven... and hell
    'He will always be a friend': Jackie Stewart backs Polanski

    'He will always be a friend'

    Jackie Stewart backs Roman Polanski
    The price of pacifism: Refusing to go to war is finally being recognised as a brave act

    The price of pacifism

    From the Second World War refusenik to the 19-year-old Israeli, Holly Williams talks to five people who risked shame and suffering to take a stand as conscientious objector.
    'It was mass hysteria': Jason Isaacs on groupies, theatre bores and snogging James Bond

    Jason Isaacs: Groupies, theatre bores and James Bond

    To millions, Jason Isaacs is one of Harry Potter's arch enemies – but his wife prefers him as a Scottish TV detective.
    Notes from a small island: Is Sealand an independent 'micronation' or an illegal fortress?

    Sealand: 'Micronation' or illegal fortress?

    Thomas Hodgkinson spent a week at the tiny platform off the Suffolk coast to find out.
    Not a bad bone: Mark Hix cooks with cutlets and ribs

    Mark Hix cooks with cutlets and ribs

    If you ignore cutlets and ribs, you'll risk missing out on some delicious and easy meals, says our chef.
    The experts' guide to summer: From getting fit for the beach to recreating that Olympic buzz

    The experts' guide to summer

    From getting fit for the beach to recreating that Olympic buzz
    Sex, drugs and fast cars: The legend of James Hunt has set Hollywood hearts racing

    Legend of James Hunt has set Hollywood hearts racing

    Early glimpses of Ron Howard's film Rush suggest it will portray Hunt as a high-living lothario, with an insatiable appetite for partying.
    Macklemore: 'I don't have moderation when using drugs and alcohol. It was hurting my life'

    Macklemore: 'I don't have moderation'

    The next Vanilla Ice or the next Eminem? Macklemore doesn't have a record contract – but he does have the UK's biggest-selling single of the year.
    Don't be shy: Bill Granger's Sri Lankan recipes

    Don't be shy: Bill Granger's Sri Lankan recipes

    Sri Lankan cuisine is light, sunny, wonderfully spiced – and so easy to cook from scratch. Just as soon as you've broken into the coconut, that is.
    Sir James Dyson’s latest project: Cleaning up hospitals

    Sir James Dyson’s latest project: Cleaning up hospitals

    Doctors are hailing the revamp of a Bath neonatal unit, where babies sleep more and feed better, as the model for patient care
    One man returns to Argentina's town that drowned

    One man returns to Argentina's town that drowned

    Epecuen was submerged under 10 metres of water in 1985. Now the floods have gone – and 83-year-old Pablo Novak has moved back in